xpressing concerns about generic competition, a House committee asked Allergan (AGN) to provide a slew of documents about its controversial deal to sell patents on a best-selling drug to a Native American tribe.

In a letter sent on Tuesday to Allergan chief executive officer Brent Saunders, the Committee on Oversight and Government Reform wants the drug maker to cough up agreements, contracts, and analysis pertaining to the sale. An Allergan spokesman wrote us that the company intends to comply with the request.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy